High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.
暂无分享,去创建一个
Ryan D. Morin | Lauren C. Chong | R. Gascoyne | R. Siebert | D. Scott | L. Sehn | J. Connors | A. Mottok | D. Ennishi | P. Farinha | S. Ben-Neriah | R. Kridel | P. Abrisqueta | M. Boyle | B. Meissner | K. Savage | G. Slack | C. Steidl | M. Marra | R. Morin | A. Mungall | C. Freeman | D. Villa | A. Gerrie | L. Chong | B. Collinge
[1] A. Lauritzen,et al. MYC translocation partner gene determines survival of patients with large B‐cell lymphoma with MYC‐ or double‐hit MYC/BCL2 translocations , 2014, European journal of haematology.
[2] R. Yeh,et al. Identification of two distinct MYC breakpoint clusters and their association with various IGH breakpoint regions in the t(8;14) translocations in sporadic Burkitt-lymphoma , 2007, Leukemia.
[3] F. Jardin,et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas , 2007, Leukemia.
[4] Shawn M. Gillespie,et al. Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. , 2015, Cancer discovery.
[5] Thomas Zichner,et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..
[6] R. Spang,et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma , 2014, Haematologica.
[7] A. Rosenwald,et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. , 2018, Blood.
[8] R. Spang,et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.
[9] M. Dyer,et al. BCL2 translocations in leukemias of mature B cells. , 1994, Blood.
[10] R. Aguiar,et al. A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. , 2013, Blood.
[11] E. Obermann,et al. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment , 2009, Journal of Clinical Pathology.
[12] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[13] Ryan D. Morin,et al. Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas. , 2016, Blood.
[14] A. Ariza,et al. MYC status determination in aggressive B‐cell lymphoma: the impact of FISH probe selection , 2013, Histopathology.
[15] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Advani,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .
[17] A. Dogan,et al. Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2 , 2006, Leukemia.
[18] Steven J. M. Jones,et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. , 2013, Blood.
[19] R. Gascoyne,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.
[20] Ken H. Young,et al. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma , 2015, Oncotarget.
[21] D. Arber,et al. ''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. , 2007, The Journal of molecular diagnostics : JMD.
[22] E. Thiel,et al. Molecular analysis of the t(2;8)/MYC–IGK translocation in high‐grade lymphoma/leukemia by long‐distance inverse PCR , 2012, Genes, chromosomes & cancer.
[23] Andreas Trumpp,et al. A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies , 2018, Nature.
[24] M. Neat,et al. Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: implications for cytogenetic testing. , 2010, Cancer genetics and cytogenetics.
[25] A. Yoshimura,et al. The B cell‐specific major raft protein, Raftlin, is necessary for the integrity of lipid raft and BCR signal transduction , 2003, The EMBO journal.
[26] A. Rosenwald,et al. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. , 2013, Blood.
[27] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[28] A. Lauritzen,et al. Double‐hit BCL2/MYC translocations in a consecutive cohort of patients with large B‐cell lymphoma – a single centre's experience , 2012, European journal of haematology.
[29] C. Croce,et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[30] P. Lichter,et al. Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. , 1992, Human molecular genetics.
[31] Philippe Dessen,et al. Atlas of Genetics and Cytogenetics in Oncology and Haematology in 2013 , 2012, Nucleic Acids Res..
[32] G. Klein,et al. Characteristic chromosomal abnormalities in biopsies and lymphoid‐cell lines from patients with burkitt and non‐burkitt lymphomas , 1976, International journal of cancer.
[33] C. Copie-Bergman,et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. , 2015, Blood.
[34] Olivier Elemento,et al. Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. , 2016, Immunity.
[35] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[36] R. Spang,et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing , 2012, Nature Genetics.
[37] Kai Fu,et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. , 2014, Blood.
[38] G. Morgan,et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients , 2014, Blood Cancer Journal.
[39] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[40] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[41] M. Rocchi,et al. Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma , 2003, Genes, chromosomes & cancer.
[42] J. Friedberg. How I treat double-hit lymphoma. , 2017, Blood.
[43] Scott E. Smith,et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. , 2014, Blood.
[44] A. Aventín,et al. A variant translocation t(2;18) in follicular lymphoma involves the 5' end of bcl-2 and Ig kappa light chain gene. , 1991, Oncogene.
[45] E. Haralambieva,et al. BCL6 alternative translocation breakpoint cluster region associated with follicular lymphoma grade 3B , 2005, Genes, chromosomes & cancer.
[46] Patrice Duroux,et al. IMGT®, the international ImMunoGeneTics information system® 25 years on , 2014, Nucleic Acids Res..
[47] M. Lieber. Mechanisms of human lymphoid chromosomal translocations , 2016, Nature Reviews Cancer.
[48] A. Rosenwald,et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.
[49] Ioannis Panagopoulos,et al. Atlas of Genetics and Cytogenetics in Oncology and Haematology , 2005 .
[50] P. Leder,et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.